All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub hosted a virtual Satellite Symposium on the management and treatment of patients with relapsed/refractory (R/R) lymphoma. Professor Marie José Kersten, Amsterdam UMC, Amsterdam, NL, discussed how she would manage a patient with R/R diffuse large B-cell lymphoma (DLBCL) following relapse to chimeric antigen receptor (CAR) T-cell therapy.
Satellite Symposium | Patient with R/R DLBCL— European perspective
Marie-José Kersten provides an overview of the pivotal clinical trials evaluating CAR T-cell treatments for DLBCL, and the most widely understood mechanisms of resistance to CD19-directed CAR T-cell therapy.
After outlining a number of novel CAR-T constructs, she proceeds to discuss non-CAR T-based therapies and relevant clinical trial opportunities for the patient. These include studies evaluating bispecific antibodies, including epcoritamab and blinatumomab, and the CDK9 inhibitor AZD4573.
Satellite Symposium | Patient with R/R DLBCL— European perspective
If you would like to download the slides from Marie José Kersten's presentation, click below.
Download hereUnderstanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox